Osimertinib (Tagrisso®) Adjuvant treatment stage IB-IIIA NSCLC. HTA ID: 21066

Assessment Status NCPE Assessment Process Complete
HTA ID 21066
Drug Osimertinib
Brand Tagrisso®
Indication For adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer whose tumour has epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Assessment Process
Rapid review commissioned 20/12/2021
Rapid review completed 13/01/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/01/2022
Pre-submission consultation with Applicant 15/03/2022
Full submission received from Applicant 16/08/2022
Preliminary review sent to Applicant 27/01/2023
NCPE assessment re-commenced 13/03/2023
Factual accuracy sent to Applicant 03/05/2023
NCPE assessment re-commenced 10/05/2023
NCPE assessment completed 23/05/2023
NCPE assessment outcome The NCPE recommends that osimertinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations March 2024.